Key Points
- CEO Jerome Durso bought 30,700 Altimmune shares at an average $1.62 each, investing about $49,734. The purchase increased his holdings by 49.12% to 93,200 shares.
- Altimmune reported a quarterly loss of $0.15 per share, missing analysts’ $0.13 loss estimate by $0.02.
- Shares traded at $1.65, near their 12-month low of $1.58. Analysts’ average rating was “Moderate Buy,” with an average price target of $14.33.
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CFO Gregory Weaver bought 10,000 shares of the company's stock in a transaction on Friday, November 13th. The stock was bought at an average cost of $1.62 per share, for a total transaction of $16,200.00. Following the completion of the acquisition, the chief financial officer directly owned 73,005 shares of the company's stock, valued at approximately $118,268.10. This represents a 15.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Altimmune Stock Performance
ALT traded up $0.04 during midday trading on Friday, hitting $1.65. 3,528,857 shares of the company traded hands, compared to its average volume of 3,885,901. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07. The company's 50-day moving average is $2.58 and its 200 day moving average is $3.15. Altimmune, Inc. has a 52 week low of $1.58 and a 52 week high of $6.44. The firm has a market capitalization of $319.99 million, a PE ratio of -2.28 and a beta of 0.16.
Altimmune (NASDAQ:ALT - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). On average, research analysts expect that Altimmune, Inc. will post -0.58 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers grew its position in Altimmune by 19.4% in the first quarter. Cetera Investment Advisers now owns 35,453 shares of the company's stock worth $109,000 after acquiring an additional 5,766 shares during the period. Vontobel Holding Ltd. boosted its stake in shares of Altimmune by 23.1% in the third quarter. Vontobel Holding Ltd. now owns 30,787 shares of the company's stock valued at $88,000 after purchasing an additional 5,787 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Altimmune by 26.0% in the first quarter. The Manufacturers Life Insurance Company now owns 34,763 shares of the company's stock worth $107,000 after acquiring an additional 7,167 shares in the last quarter. Parallel Advisors LLC increased its holdings in Altimmune by 21,755.0% during the 3rd quarter. Parallel Advisors LLC now owns 8,742 shares of the company's stock worth $25,000 after purchasing an additional 8,702 shares during the period. Finally, AXQ Capital LP raised its holdings in Altimmune by 19.0% in the second quarter. AXQ Capital LP now owns 56,810 shares of the company's stock valued at $173,000 after acquiring an additional 9,058 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the company. Wall Street Zen lowered Altimmune from a "sell" rating to a "strong sell" rating in a research report on Saturday. B. Riley Financial restated a "buy" rating on shares of Altimmune in a report on Friday. Citigroup reaffirmed a "market outperform" rating on shares of Altimmune in a research report on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Altimmune in a report on Monday, September 21st. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Altimmune in a research report on Tuesday, July 28th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $14.33.
Check Out Our Latest Stock Analysis on ALT
Altimmune News Roundup
Here's some of the latest news about ALT:
- Positive Sentiment: CEO Jerome Durso, CFO Gregory Weaver, and director Wayne Pisano reported open-market purchases totaling 50,700 shares at prices of $1.62–$1.64. The buys increased each executive’s or director’s holdings and may signal confidence in the company. CEO filing CFO filing Director filing
- Neutral Sentiment: B. Riley reaffirmed its Buy rating, providing supportive analyst sentiment, although the rating is not a guarantee of future performance.
- Negative Sentiment: A Seeking Alpha analysis characterized pemvidutide’s development as late and capital-intensive, underscoring the risk that lengthy trials and spending could weigh on ALT before any potential product revenue. Analysis
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune's work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
